Black Diamond Therapeutics, Inc.
NASDAQ:BDTXBiotechnology
-$0.04 today
- Market cap
- $82.18M
- Beta
- 3.23
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$0.75
Volume 0.60M
Average 1.31M
BDTX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Black Diamond Therapeutics, Inc.NASDAQ: BDTX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $4.26M fell 14.3% year over year, ahead of the -38.3% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 7.3% from the prior quarter. Over 3 fiscal years it compounded at -16.4% a year.
Context
- Selling, general & admin amounted to 23.7% of revenue in FY2025.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $7.06M (-57.4%) for the fiscal year ending Dec 2026, a slowdown from the -39.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $4.26M+7.3% QoQ
- Last fiscal yearDec 2025
- $16.57M-39.7% YoY
- LTMMar 2026
- $15.86M-38.3% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 16.57M USD
- Year-over-year change
- -39.7%
- 4-year CAGR
- -13.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.57M | -39.7% |
| FY2024 | 2024-12-31 | 27.47M | +1.3% |
| FY2023 | 2023-12-31 | 27.11M | -4.5% |
| FY2022 | 2022-12-31 | 28.39M | -5.5% |
| FY2021 | 2021-12-31 | 30.04M | — |
Selling, General & Admin vs competitors
How BDTX compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -38.3% is the lowest of 11, against a peer median of +28.1%.
- Over three fiscal years its annual growth of -16.4% compares with a peer median of +3.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.7B USD | +29505.3% | +3.5% | — | |
| LTM Mar 2026 | $73.88M USD | +132.8% | +55.6% | 508.1% | |
| FY2025 | €53.89M EUR | +215.2% | +51.5% | 1202.1% | |
| LTM Mar 2026 | $52.43M USD | +32.8% | +31.8% | 102.8% | |
| LTM Mar 2026 | $38.28M USD | -25.4% | -1.1% | 55.3% | |
| LTM Mar 2026 | $36.25M USD | -1.5% | -0.1% | 323.5% | |
| LTM Mar 2026 | $26.89M USD | -3.6% | -3.6% | 95.3% | |
| LTM Mar 2026 | $24.19M USD | +23.5% | +3.4% | 41000.0% | |
| LTM Mar 2026 | $23.71M USD | -4.5% | +3.4% | 10537.3% | |
| LTM Mar 2026 | $16.97M USD | +137.1% | +72.2% | — | |
| LTM Mar 2026 | $15.86M USD | -38.3% | -16.4% | — | |
| Peer median (excluding BDTX) | — | +28.1% | +3.4% | 415.8% | |
Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 70M |
| Cost of Revenue | 0 | 0 | 437K | 0 | 325K |
| Gross Profit | 0 | 0 | (437K) | 0 | 69.68M |
| Gross Margin | — | — | — | — | 99.5% |
| Research & Development | 96.83M | 64.44M | 58.91M | 51.31M | 33.56M |
| Selling, General & Admin | 30.04M | 28.39M | 27.11M | 27.47M | 16.57M |
| Operating Expenses | 126.87M | 92.83M | 86.02M | 78.78M | 49.81M |
| Depreciation & Amortization | 205K | 508K | 437K | 343K | 325K |
| EBITDA | (125.39M) | (90.66M) | (82.01M) | (69.33M) | 22.69M |
| EBITDA Margin | — | — | — | — | 32.4% |
| Operating Income | (126.87M) | (92.83M) | (86.46M) | (78.78M) | 19.87M |
| Operating Margin | — | — | — | — | 28.4% |
| Interest Income | 3.46M | 2.03M | 1.92M | 2.18M | 4.06M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.28M | 1.66M | 4.02M | 9.11M | 2.5M |
| Income Before Tax | (125.6M) | (91.17M) | (82.44M) | (69.68M) | 22.37M |
| Pre-Tax Margin | — | — | — | — | 32.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (125.6M) | (91.17M) | (82.44M) | (69.68M) | 22.37M |
| Net Margin | — | — | — | — | 32.0% |
| EPS (Basic) | (3.47) | (2.52) | (1.88) | (1.27) | 0.39 |
| EPS (Diluted) | (3.47) | (2.52) | (1.88) | (1.27) | 0.39 |
| Weighted Avg Shares | 36.19M | 36.23M | 43.95M | 55.03M | 56.87M |
| Weighted Avg Shares (Diluted) | 36.19M | 36.23M | 43.95M | 55.03M | 57.56M |
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
Intrinsic Alpha fair value
Locked
Current Price
$1.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.